跳至主要内容
临床试验/NCT02357485
NCT02357485已完成1 期

Adipose Derived Stromal Cell (ADSC) Injections for Pain Management of Osteoarthritis in the Human Knee Joint

Fodor, Peter B, M.D.0 个研究点目标入组 6 人开始时间: 2014年3月1日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
6
主要终点
Safety as Measured by Adverse Events

研究概览

简要总结

This safety and feasibility study used autologous adipose-derived stromal cells (ADSC), the stromal vascular fraction (SVF), to treat 8 osteoarthritic (OA) knees in 6 patients of grade I to III (K-L scale) with initial pain of 4 or greater on a 10 point scale, under Institutional Review Board (IRB) approved protocol.

详细描述

This safety and feasibility study used autologous adipose-derived stromal cells, the stromal vascular fraction, to treat 8 osteoarthritic knees in 6 patients of grade I to III (K-L scale) with initial pain of 4 or greater on a 10 point scale, under IRB-approved protocol. Evaluation of the safety of intra-articular injection of the stromal vascular fraction cells was the primary objective of the study. Adipose-derived stromal vascular cells were obtained through enzymatic disaggregation of lipoaspirate, resuspended in 3 ml of Lactated Ringer's Solution, and injected directly into the intra-articular space with a mean of 12 million viable nucleated SVF cells per knee.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • voluntarily provided written Informed Consent
  • ages 20-70
  • male or female
  • grades I-III radiologically documented OA of one or both knees
  • American Society Anaesthesiologists (ASA) physical status class I-II and a • BMI less than 35
  • knee pain graded as greater than 3 out of 10 on screening questionnaire
  • able to speak, read and understand English -

排除标准

  • patient parameters falling outside of the inclusion criteria
  • current oral or parenteral steroid or blood thinner use
  • hyaluronic acid-based injection to the affected knee joint within the previous six months
  • corticosteroid injection to the affected knee joint within the previous three months
  • end stage (Grade IV) OA

结局指标

主要结局

Safety as Measured by Adverse Events

时间窗: Entire Study (1 year)

Adverse Events were recorded during the entirety of the study.

次要结局

  • Comparison of Baseline Score and 3 Months Score in Timed-Up-and-Go (TUG).(baseline to 3 months)
  • Comparison of Baseline Score and 1 Year Score in Western Ontario and McMaster Universities Arthritis Index (WOMAC)(Baseline to 1 year)
  • Comparison of Baseline and 3 Months Measures of Knee Flexion for Range of Motion(Baseline to 3 months)
  • Comparison of Baseline Score and 1 Year Score in Visual Analog Scale (VAS) for Pain(Baseline to 1 year)

研究者

发起方
Fodor, Peter B, M.D.
申办方类型
Indiv
责任方
Principal Investigator
主要研究者

Peter B. Fodor MD

Peter B. Fodor, M.D.

Fodor, Peter B, M.D.

相似试验

ADSC Injections for Pain Management of... | 临床试验